scholarly journals Selective Cytotoxic Potential of IFN-γ and TNF-α on Breast Cancer Cell Lines (T47D and MCF7)

2015 ◽  
Vol 11 (1) ◽  
pp. 1-12 ◽  
Author(s):  
Wahyu Widowati ◽  
Harry Murti ◽  
Diana Krisanti Jasaputra ◽  
Sutiman B. Sumitro ◽  
M. Aris Widodo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Cytotoxic Potential ◽  
Tnf Α ◽  
Ifn Γ

PXR and NF-κB correlate with the inducing effects of IL-1β and TNF-α on ABCG2 expression in breast cancer cell lines

2012 ◽  
Vol 47 (2) ◽  
pp. 474-480 ◽  
Author(s):  
Obeid M. Malekshah ◽  
Hermann lage ◽  
Ahmad Reza Bahrami ◽  
Jalil Tavakol Afshari ◽  
Javad Behravan
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Tnf Α

Genetically Modified Her2-Specific T Cells Recognize Low and High Her2 Expressing Breast Cancer Cells.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5540-5540
Author(s):  
Nabil M. Ahmed ◽  
Maheshika Ratnayake ◽  
Martin Pule ◽  
Cliona M. Rooney ◽  
Helen E. Heslop ◽  
...  
Keyword(s):  
Breast Cancer ◽  
T Cells ◽  
T Cell ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Ifn Γ ◽  
Low Levels

Abstract Background: Only patients with breast cancers expressing high levels of Her2 benefit from anti-Her2 monoclonal antibodies such as trastuzumab. In the present study we investigated in vitro, if chimeric T-cell receptors (TCR), which combine the antigen-specificity of monoclonal antibodies with the effector function of T cells can overcome this limitation. Material and Methods: T cells from healthy donors were transduced with retroviral vectors containing the Her2-specific chimeric TCR gene with a CD28-zeta signaling domain (Her2-CD28-zeta). The specificity of the genetically modified T cells was determined by their ability 1) to kill breast cancer cell lines in cytoxicity assays, and 2) to proliferate and secrete cytokines (IFN-γ and IL-2) after stimulation with breast cancer cell lines. The following panel of cell lines was used: autologous PHA blasts, MDA-MB-468 (both Her2-negative), MCF-7 (Her2-low), Her218 and SKBR-3 (both Her2-high). Results: Her2-CD28-zeta expressing T cells killed low and high Her2-positive breast cancer cell lines in cytotoxicity assays, where as Her2-negative T cells were not killed. Stimulation of T cells with breast cancer cell lines expressing both high and low levels of Her2 resulted in T-cell proliferation and secretion of IFN-γ and IL-2 in a HER2 dependent manner. Discussion: We demonstrate that breast cancer cells with low levels of expression of Her2 can effectively activate T cells expressing Her2-specific chimeric T cell receptor, induce T-cell proliferation, and the production of IL-2, an important T-cell growth factor. These results indicate that T cells expressing chimeric TCRs could possibly extend the application of Her2 targeted therapies to malignancies expressing low levels of Her2.

Cytotoxic activity and anti-cancer potential of Ontario grown onion extracts against breast cancer cell lines

2018 ◽  
Vol 8 (3) ◽  
pp. 159 ◽  
Author(s):  
Meghan Fragis ◽  
Abdulmonem I. Murayyan ◽  
Suresh Neethirajan
Keyword(s):  
Breast Cancer ◽  
Cytotoxic Activity ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Cytotoxic Activities ◽  
Cancer Line ◽  
Mcf 7

Background: Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths among Canadian women. Cancer management through changes in lifestyle, such as increased intake of foods rich in dietary flavonoids, have been shown to decrease the risk associated with breast, liver, colorectal, and upper-digestive cancers in epidemiologic studies. Onions are high in flavonoid content and one of the most common vegetables. Additionally, onions are used in most Canadian cuisines.Methods: We investigated the effect of five prominent Ontario grown onion (Stanley, Ruby Ring, LaSalle, Fortress, and Safrane) extracts on two subtypes of breast cancer cell lines: a triple negative breast cancer line MDA-MB-231 and an ER+ breast cancer line MCF-7.Results: These onion extracts elicited strong anti-proliferative, anti-migratory, and cytotoxic activities on both the cancer cell lines. Flavonoids present in these onion extracts induced apoptosis, cell cycle arrest in the G2/M phase, and a reduction in mitochondrial membrane potential at dose-dependent concentrations. Onion extracts were more effective against MDA-MB-231 compared to the MCF-7 cell line. Conclusion: In this study, we investigated the extracts synthesized from Ontario-grown onion varieties in inducing anti-migratory, cytostatic, and cytotoxic activities in two sub-types of human breast cancer cell lines. Anti-tumor activity of these extracts depends upon the varietal and can be formulated into nutraceuticals and functional foods for the wellbeing of cancer patients. Overall, the results suggest that onion extracts are a good source of flavonoids with anti-cancerous properties.Keywords: onion extracts; flavonoids; anti-proliferative; breast cancer; cytotoxic activity

ANTITUMOR EFFECT OF SUNITINIB AND BORTEZOMIB ON BREAST CANCER CELL LINE IN VITRO

2017 ◽  
Vol 63 (1) ◽  
pp. 141-145
Author(s):  
Yuliya Khochenkova ◽  
Eliso Solomko ◽  
Oksana Ryabaya ◽  
Yevgeniya Stepanova ◽  
Dmitriy Khochenkov
Keyword(s):  
Breast Cancer ◽  
Cell Line ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Antitumor Effect ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Actual Problem

The discovery for effective combinations of anticancer drugs for treatment for breast cancer is the actual problem in the experimental chemotherapy. In this paper we conducted a study of antitumor effect of the combination of sunitinib and bortezomib against MDA-MB-231 and SKBR-3 breast cancer cell lines in vitro. We found that bortezomib in non-toxic concentrations can potentiate the antitumor activity of sunitinib. MDA-MB-231 cell line has showed great sensitivity to the combination of bortezomib and sunitinib in vitro. Bortezomib and sunitinib caused reduced expression of receptor tyrosine kinases VEGFR1, VEGFR2, PDGFRa, PDGFRß and c-Kit on HER2- and HER2+ breast cancer cell lines

Sign in / Sign up

Export Citation Format

Share Document